摘要
目的:探讨金水宝片辅助治疗艾滋病合并肺结核对HIV-RNA载量及CD4^(+)T细胞的影响。方法:选取2022年1月—2024年1月赣州市第五人民医院收治的艾滋病合并肺结核患者105例,按照随机数字表法将纳入患者分为对照组(n=52)和观察组(n=53)共两组,其中对照组采用常规西医治疗(高效抗反转录病毒+抗结核方案),在此基础上观察组采用金水宝片治疗。比较两组临床疗效,治疗前后HIV-RNA载量、CD4^(+)T细胞数水平差异及用药不良反应发生率。结果:观察组治疗总有效率为94.34%(50/53),对照组为78.85%(41/52),观察组总有效率与对照组相比更高,差异有统计学意义(P<0.05)。治疗1、6个月两组患者HIV-RNA载量与治疗前相比均下降,CD4^(+)T细胞数与治疗前相比均上升,差异有统计学意义(P<0.05);且观察组患者治疗1、6个月HIV-RNA载量与同期对照组相比水平更低,CD4^(+)T细胞数与同期对照组相比水平更高,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率为9.43%(5/53),对照组为7.69%(4/52),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:金水宝片辅助治疗艾滋病合并肺结核效果显著,能有效降低患者HIV-RNA载量,提高机体免疫功能,且用药安全性良好。
Objective:To investigate the effect of Jinshuibao Tablets on HIV-RNA load and CD4^(+)T cells in adjuvant treatment of AIDS patients complicated with pulmonary tuberculosis.Method:A total of 105 cases of AIDS patients complicated with pulmonary tuberculosis admitted to the Fifth People's Hospital of Ganzhou from January 2022 to January 2024 were selected.According to the random number table,the patients were divided into two groups:the control group(n=52)and the observation group(n=53).The control group was treated with conventional western medicine(highly effective antiretroviral+antituberculosis program),and the observation group was treated with Jinshuibao Tablets on this basis.The clinical efficacy,differences in HIV-RNA load,CD4^(+)T cell count levels before and after treatment,and incidence of adverse drug reactions between two groups were compared.Result:The total effective rate of the observation group was 94.34%(50/53),while the control group was 78.85%(41/52),the total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).The HIV-RNA load of both groups of patients after 1 month and 6 months of treatment decreased compared to those before treatment,while the CD4^(+)T cell count increased compared to those before treatment,with statistically significant differences(P<0.05);moreover,the HIV-RNA load and CD4^(+)T cell count in the observation group were lower and higher than those in the control group after 1 month and 6 months of treatment,with statistically significant differences(P<0.05).During the treatment period,the incidence of adverse reactions in the observation group was 9.43%(5/53),while in the control group was 7.69%(4/52),there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Jinshuibao Tablets is effective in the adjuvant treatment of AIDS patients complicated with pulmonary tuberculosis,it can effectively reduce the HIVRNA load of patients,improve the immune function of the body,and has good drug safety.
作者
王培兴
彭海英
孙玉霞
曾江
WANG Peixing;PENG Haiying;SUN Yuxia;ZENG Jiang(Department of Clinical Laboratory,the Fifth People's Hospital of Ganzhou,Ganzhou 341000,China;不详)
出处
《中国医学创新》
2025年第28期24-27,共4页
Medical Innovation of China
基金
江西省中医院管理局科技计划课题(2022B1077)。
